Who
Natasha Hernday
Director
Company insider
Files Form 4 as: Director, XOMA Royalty; Director, Janux Therapeutics; Director, Alpine Immune Sciences; Director, Pdl Biopharma.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 20 Jun 2019
- Last trade
- 14 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 14 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code J | —9,304 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code D | —4,000 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —13,251 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —13,251 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —5,101 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —8,996 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —10,967 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —4,881 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,101 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,996 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,967 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,881 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royalty | SEC FORM 4 Code J | —9,304 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royalty | SEC FORM 4 Code D | —4,000 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code A | —3,586 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | XOMA Royalty | SEC FORM 4 Code A | —3,586 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.